Search
Transcode Therapeutics Inc
RNAZAdd to Watchlist
6.210USD
+0.970+18.51%
Close 06/30, 16:00（ET）Quotes delayed by 15 min
5.90MMarket Cap
LossP/E TTM
More Details of Transcode Therapeutics Inc Company
TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. It is defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its lead candidate, TTX-MC138, targets metastatic tumors overexpressing microRNA-10b, a biomarker of metastasis. The Company is also developing a portfolio of RNA therapeutic candidates to overcome delivery challenges and unlock access to novel genetic targets. Its preclinical programs include TTX-siPDL1 (siRNA modulator of PD-L1), TTX-RIGA (RNA agonist of RIG-I for innate immunity activation), and TTX-siMYC (siRNA inhibitor of c-MYC). Additionally, R&D efforts are exploring the combination of TTX-MC138 and seviprotimut-L technologies to enhance therapeutic impact.
Transcode Therapeutics Inc Info
Ticker SymbolRNAZ
Company nameTranscode Therapeutics Inc
IPO dateApr 28, 2021
CEOCalais (Philippe P)
Number of employees7
Security typeOrdinary Share
Fiscal year-endApr 28
Address6 Liberty Square
CityBOSTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02109
Phone18573016857
Websitehttps://www.transcodetherapeutics.com/
Ticker SymbolRNAZ
IPO dateApr 28, 2021
CEOCalais (Philippe P)
Company Executives of Transcode Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Thomas A. (Tom) Fitzgerald
Mr. Thomas A. (Tom) Fitzgerald
Chief Financial Officer, Vice President, Director
Chief Financial Officer, Vice President, Director
3.00
--
Dr. Philippe P. Calais, Ph.D.
Dr. Philippe P. Calais, Ph.D.
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
2.00
--
Dr. Erik Manting, Ph.D.
Dr. Erik Manting, Ph.D.
Independent Director
Independent Director
--
--
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
--
--
Dr. Daniel Vlock
Dr. Daniel Vlock
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Elizabeth Czerepak
Ms. Elizabeth Czerepak
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Thomas A. (Tom) Fitzgerald
Mr. Thomas A. (Tom) Fitzgerald
Chief Financial Officer, Vice President, Director
Chief Financial Officer, Vice President, Director
3.00
--
Dr. Philippe P. Calais, Ph.D.
Dr. Philippe P. Calais, Ph.D.
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
2.00
--
Dr. Erik Manting, Ph.D.
Dr. Erik Manting, Ph.D.
Independent Director
Independent Director
--
--
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
--
--
Dr. Daniel Vlock
Dr. Daniel Vlock
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Elizabeth Czerepak
Ms. Elizabeth Czerepak
Independent Director
Independent Director
--
--
FAQs
Who are the top five shareholders of Transcode Therapeutics Inc?
The top five shareholders of Transcode Therapeutics Inc are: Mr. Thomas A. (Tom) Fitzgerald
How many institutions hold shares of Transcode Therapeutics Inc (RNAZ)?
As of 2026Q1, 37 institutions hold shares of Transcode Therapeutics Inc, with a combined market value of approximately 77.85K, accounting for 8.49% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -42306.00.